ELCC 2022 Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metast... Read more
ELCC 2022 Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutated lung adenocarci... Read more
ELCC 2022 Savolitinib in the treatment of patients with non-small cell lung cancer and MET exon 14 skipp... Read more
